Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 7/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20657254 | 0.78 | SRC (0.35) | SRCPTGDRPTGDR2IMPDH2HTR6 | |
| SCHEMBL16916209 | 0.78 | CNR2 (0.38) | SRCMAOBMAOAPTGDR2IMPDH2 | |
| SCHEMBL20657207 | 0.77 | KDM4E (0.43) | SRCMAOBMAOAIMPDH2HTR6 | |
| SCHEMBL20657190 | 0.74 | KDM1A (0.62) | — | |
| SCHEMBL20673178 | 0.72 | PPARG (0.44) | SRCIMPDH2HTR6CNR2BRD4 | |
| SCHEMBL29208197 | 0.72 | SRC (0.39) | SRCMAOBMAOAPTGDRPTGDR2 | |
| SCHEMBL20595084 | 0.71 | HTR6 (0.52) | HTR6BRD4LMNA | |
| SCHEMBL2432894 | 0.68 | BRD4 (0.43) | SRCMAOAPTGDRPTGDR2IMPDH2 | |
| SCHEMBL2110900 | 0.67 | HTR6 (0.44) | SRCHTR6CNR2LMNA | |
| SCHEMBL25423168 | 0.67 | SRC (0.41) | SRCPTGDRPTGDR2HTR6CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642195-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| CN-111032641-A | Substituted 5-cyanoindole compounds and uses thereof | 诺华股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| WO-2018234978-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | KDM1A, KDM5A, KDM1B | SRC 2006/4885MAOB 189/4885MAOA 187/4885 |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | KDM1A, KDM5A, KDM1B | SRC 2006/4885MAOB 189/4885MAOA 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.